TransMedics Group, Inc. (NASDAQ:TMDX) Receives $131.80 Average PT from Analysts

TransMedics Group, Inc. (NASDAQ:TMDX) has earned an average rating of “Moderate Buy” from the eleven research firms that are currently covering the company, MarketBeat Ratings reports. Two equities research analysts have rated the stock with a hold rating, eight have assigned a buy rating and one has assigned a strong buy rating to the company. The average twelve-month target price among brokerages that have updated their coverage on the stock in the last year is $131.80.

A number of equities analysts have weighed in on TMDX shares. Canaccord Genuity Group dropped their price target on shares of TransMedics Group from $109.00 to $104.00 and set a “buy” rating for the company in a research report on Wednesday, November 20th. Baird R W raised shares of TransMedics Group to a “strong-buy” rating in a report on Tuesday, September 24th. Oppenheimer reissued an “outperform” rating and set a $125.00 price target on shares of TransMedics Group in a report on Tuesday. Robert W. Baird dropped their price objective on TransMedics Group from $200.00 to $150.00 and set an “outperform” rating for the company in a research note on Tuesday, October 29th. Finally, TD Cowen decreased their target price on TransMedics Group from $175.00 to $120.00 and set a “buy” rating on the stock in a research note on Monday, November 18th.

Insider Transactions at TransMedics Group

In other TransMedics Group news, Director Edward M. Basile sold 6,750 shares of the business’s stock in a transaction that occurred on Tuesday, November 5th. The stock was sold at an average price of $83.55, for a total transaction of $563,962.50. Following the sale, the director now directly owns 732 shares of the company’s stock, valued at $61,158.60. The trade was a 90.22 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available through this link. Also, insider Tamer I. Khayal sold 2,958 shares of the firm’s stock in a transaction that occurred on Tuesday, October 1st. The shares were sold at an average price of $148.24, for a total value of $438,493.92. Following the completion of the sale, the insider now directly owns 20,843 shares of the company’s stock, valued at $3,089,766.32. The trade was a 12.43 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold 26,958 shares of company stock valued at $3,470,328 in the last ninety days. Corporate insiders own 7.00% of the company’s stock.

Hedge Funds Weigh In On TransMedics Group

Several large investors have recently modified their holdings of TMDX. Vanguard Group Inc. boosted its stake in TransMedics Group by 1.3% during the first quarter. Vanguard Group Inc. now owns 1,889,094 shares of the company’s stock worth $139,680,000 after buying an additional 23,979 shares during the period. Price T Rowe Associates Inc. MD grew its holdings in TransMedics Group by 8.1% during the 1st quarter. Price T Rowe Associates Inc. MD now owns 297,324 shares of the company’s stock valued at $21,985,000 after purchasing an additional 22,223 shares during the last quarter. Public Employees Retirement System of Ohio purchased a new stake in TransMedics Group in the 1st quarter worth about $1,588,000. Comerica Bank raised its position in TransMedics Group by 1,072.5% in the 1st quarter. Comerica Bank now owns 14,422 shares of the company’s stock worth $1,066,000 after purchasing an additional 13,192 shares during the period. Finally, Cetera Advisors LLC bought a new stake in TransMedics Group in the first quarter worth about $392,000. Institutional investors own 99.67% of the company’s stock.

TransMedics Group Price Performance

Shares of TransMedics Group stock opened at $71.44 on Friday. The stock has a market cap of $2.40 billion, a P/E ratio of 76.00 and a beta of 2.06. The company has a debt-to-equity ratio of 2.42, a quick ratio of 7.33 and a current ratio of 8.20. The stock’s fifty day moving average is $108.52 and its 200 day moving average is $135.34. TransMedics Group has a one year low of $68.84 and a one year high of $177.37.

TransMedics Group (NASDAQ:TMDX) last posted its quarterly earnings data on Monday, October 28th. The company reported $0.12 EPS for the quarter, missing the consensus estimate of $0.29 by ($0.17). The company had revenue of $108.76 million during the quarter, compared to the consensus estimate of $115.00 million. TransMedics Group had a return on equity of 18.74% and a net margin of 8.14%. The firm’s quarterly revenue was up 63.7% compared to the same quarter last year. During the same period last year, the business earned ($0.12) EPS. Sell-side analysts anticipate that TransMedics Group will post 1.01 earnings per share for the current year.

TransMedics Group Company Profile

TransMedics Group, Inc, a commercial-stage medical technology company, engages in transforming organ transplant therapy for end-stage organ failure patients in the United States and internationally. The company offers Organ Care System (OCS), a portable organ perfusion, optimization, and monitoring system that utilizes its proprietary and customized technology to replicate near-physiologic conditions for donor organs outside of the human body.